These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 16925496

  • 1. Vaccination: role in metastatic melanoma.
    Pilla L, Valenti R, Marrari A, Patuzzo R, Santinami M, Parmiani G, Rivoltini L.
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1305-18. PubMed ID: 16925496
    [Abstract] [Full Text] [Related]

  • 2. Antitumor vaccination: where we stand.
    Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, Lanata L, Lemoli RM, Massaia M, Rondelli D, Zanon P, Tura S.
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [Abstract] [Full Text] [Related]

  • 3. Dendritic cell vaccination as a treatment modality for melanoma.
    Eubel J, Enk AH.
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1631-42. PubMed ID: 19895246
    [Abstract] [Full Text] [Related]

  • 4. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
    Sosman JA, Sondak VK.
    Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
    [Abstract] [Full Text] [Related]

  • 5. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.
    J Immunother; 2006 Jun; 29(5):545-57. PubMed ID: 16971810
    [Abstract] [Full Text] [Related]

  • 6. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
    Slingluff CL, Chianese-Bullock KA, Bullock TN, Grosh WW, Mullins DW, Nichols L, Olson W, Petroni G, Smolkin M, Engelhard VH.
    Adv Immunol; 2006 Jun; 90():243-95. PubMed ID: 16730266
    [Abstract] [Full Text] [Related]

  • 7. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
    Slingluff CL, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, Johansen N, Grosh WW, Yamshchikov GV, Neese PY, Patterson JW, Fink R, Rehm PK.
    Clin Cancer Res; 2007 Nov 01; 13(21):6386-95. PubMed ID: 17975151
    [Abstract] [Full Text] [Related]

  • 8. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, Punt CJ.
    Crit Rev Oncol Hematol; 2008 May 01; 66(2):118-34. PubMed ID: 18262431
    [Abstract] [Full Text] [Related]

  • 9. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL.
    Ann N Y Acad Sci; 2009 Sep 01; 1174():107-17. PubMed ID: 19769743
    [Abstract] [Full Text] [Related]

  • 10. [Vaccine strategies against melanoma].
    Ghiringhelli F, Zitvogel L.
    Med Sci (Paris); 2006 Feb 01; 22(2):183-7. PubMed ID: 16457760
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma.
    Gordon LK, Ribas A, Nusinowitz S, Butterfield LH, Glaspy JA, Economou JS, Straatsma BR.
    Control Clin Trials; 2004 Aug 01; 25(4):400-7. PubMed ID: 15296814
    [Abstract] [Full Text] [Related]

  • 14. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?
    Campoli M, Ferrone S.
    Expert Rev Vaccines; 2004 Apr 01; 3(2):171-87. PubMed ID: 15056043
    [Abstract] [Full Text] [Related]

  • 15. Immunotherapy of melanoma.
    Parmiani G, Castelli C, Rivoltini L, Casati C, Tully GA, Novellino L, Patuzzo A, Tosi D, Anichini A, Santinami M.
    Semin Cancer Biol; 2003 Dec 01; 13(6):391-400. PubMed ID: 15001157
    [Abstract] [Full Text] [Related]

  • 16. Melanoma vaccines.
    Yang JC.
    Cancer J; 2011 Dec 01; 17(5):277-82. PubMed ID: 21952276
    [Abstract] [Full Text] [Related]

  • 17. [New aspects of immunotherapy of malignant melanoma].
    Enk A.
    Praxis (Bern 1994); 2001 Mar 08; 90(10):403-6. PubMed ID: 11305186
    [Abstract] [Full Text] [Related]

  • 18. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ, Leccia MT, Lesimple T, Wijdenes J, Bartholeyns J, Fridman WH, Salcedo M, Ferries E, Tartour E.
    J Immunother; 2008 Jan 08; 31(1):101-12. PubMed ID: 18157017
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Melanoma vaccines: early progress and future promises.
    Zarour HM, Kirkwood JM.
    Semin Cutan Med Surg; 2003 Mar 08; 22(1):68-75. PubMed ID: 12773015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.